General
Preferred name
CLODRONIC ACID
Synonyms
clodronic acid disodium tetrahydrate ()
Disodium clodronate tetrahydrate ()
Clastoban ()
CLODRONATE DISODIUM ()
Clodronate ()
clodronate disodium, Abiogen ()
Clodronate (disodium tetrahydrate) ()
Clodronic acid (disodium salt) ()
Clodronate disodium tetrahydrate ()
Disodium clodronate (tetrahydrate) ()
Clodronate (disodium salt) ()
Bonefos ()
Clodronic acid disodium salt anhydrous ()
Sodium clodronate hydrate ()
Disodium clodronate ()
Clodronic acid disodium salt ()
ZK 00091106 ()
Clodronate disodium anhydrous ()
177501 ()
ZK-00091106 ()
Acide clodronique ()
Acido clodronico ()
Clodronate (sodium salt hydrate) ()
P&D ID
PD010060
CAS
88416-50-6
22560-50-5
10596-23-3
Tags
available
drug
drug candidate
First approval
1986
Drug indication
Hypercalcaemia
Pain
Bone disease
Drug Status
approved
investigational
vet_approved
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
PRICE 29
DESCRIPTION Clodronic acid disodium salt (Lodronate), a bisphosphonate, is a potent antiosteolytic agent which inhibits bone resorption.
DESCRIPTION Clodronic acid is a first generation (non-nitrogenous) bisphosphonate drug. Clinically used drugs can contain sodium clodronate tetrahydrate, sodium clodronate, disodium clodronate tetrahydrate or disodium clodronate.

Kato et al. (2017) report that clodronic acid-mediated inhibition of the vesicular nucleotide transporter (VNUT, SLC17A9) suggests that this drug has potential as a transporter-targeted (and notably, non-opioid) analgesic drug for the treatment of chronic neuropathic and inflammatory pain . In this study clodronic acid was selective for VNUT compared to other vesicular transporters tested. (GtoPdb)
DESCRIPTION Clodronate disodium tetrahydrate (Clastoban) inhibits bone resorption and soft tissue calcification. (TargetMol Bioactive Compound Library)
DESCRIPTION Matrix metalloproteinase 1 (MMP1) and collagenase inhibitor (LOPAC library)
DESCRIPTION Clodronic acid (INN) or clodronate disodium (USAN) is a first generation (non-nitrogenous) bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment of osteoporosis in post-menopausal women and men to reduce vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma and fracture related pain because of its potent anti-inflammatory and analgesic effects shown as a reduction in inflammatory markers like IL-1β, IL-6, and TNF-alfa. (BOC Sciences Bioactive Compounds)
DESCRIPTION Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
2
Compound Sets
25
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
97
Properties
(calculated by RDKit )
Molecular Weight
243.89
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
4
Rotatable Bonds
2
Ring Count
0
Aromatic Ring Count
0
cLogP
0.43
TPSA
115.06
Fraction CSP3
1.0
Chiral centers
0.0
Largest ring
0.0
QED
0.41
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
MMP1 / collagenase
Target
IL-1β
IL-6
TNF-α
IL-1¦Â
TNF-¦Á
SLC25A4, SLC25A5, SLC25A6
MOA
IL receptor
TNF inhibitor
bone resorption inhibitor
Pathway
Apoptosis
Immunology/Inflammation
Indication
osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma
Disease Area
orthopedics, endocrinology, hematologic malignancy
Therapeutic Class
Antihypocalcemic Agents
Source data